A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University College, London
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Alliance for Clinical Trials in Oncology
Children's Oncology Group
Children's Oncology Group
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
University Hospital Schleswig-Holstein
Gruppo Italiano Malattie EMatologiche dell'Adulto
Spectrum Pharmaceuticals, Inc
Alliance for Clinical Trials in Oncology
Spectrum Pharmaceuticals, Inc
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
St. Jude Children's Research Hospital
Prince of Wales Hospital, Shatin, Hong Kong
Acrotech Biopharma Inc.
Gilead Sciences
M.D. Anderson Cancer Center
Dutch Childhood Oncology Group
Therapeutic Advances in Childhood Leukemia Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
Sun Yat-sen University
Children's Oncology Group
Children's Oncology Group
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Stanford University
Children's Oncology Group
Children's Oncology Group
Memorial Sloan Kettering Cancer Center